Home

Johnson & Johnson (JNJ)

154.22
-1.44 (-0.93%)
NYSE · Last Trade: May 11th, 1:17 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Studybenzinga.com
Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.
Via Benzinga · May 9, 2025
Johnson & Johnson’s Psoriasis Drug Meets Goal In Late Stage Study: Retail Yet To Be Impressedstocktwits.com
The company said that 66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational oral Icotrokinra achieved site-specific clear or almost clear skin at week 16.
Via Stocktwits · May 9, 2025
Mattel Appoints Kenvue CFO Paul Ruh As Finance Chief As Toy Maker Navigates Tariff Challengesstocktwits.com
Before Kenvue and Johnson & Johnson, Ruh was at PepsiCo for 17 years.
Via Stocktwits · May 8, 2025
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocksbenzinga.com
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
Via Benzinga · May 8, 2025
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Boughtbenzinga.com
Marjorie Taylor Greene disclosed buying more than 50 stocks in early May. A look at the list and why the congresswoman's past trades have drawn red flags.
Via Benzinga · May 7, 2025
Recent Filing Shows That Rep. Gilbert Ray Cisneros Bought Over $106K Worth of Aris Water Solutions Stockbenzinga.com
Via Benzinga · May 7, 2025
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversightbenzinga.com
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing.
Via Benzinga · May 6, 2025
Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concernsbenzinga.com
President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new tariffs on imported medicines within two weeks
Via Benzinga · May 6, 2025
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?benzinga.com
FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases.
Via Benzinga · May 5, 2025
Donald Trump Vows To 'Call' Up CEOs Who Make Business Moves That Displease Him, Explains Why He Phoned Jeff Bezos To Scrap Amazon's Tariff Disclosurebenzinga.com
Trump claims he might personally phone CEOs for business moves he dislikes, using this tactic on Amazon's Bezos over tariff disclosures.
Via Benzinga · May 5, 2025
Analyzing JOHNSON & JOHNSON (NYSE:JNJ)'s Dividend Potential.chartmill.com
Why JOHNSON & JOHNSON (NYSE:JNJ) provides a good dividend, while having solid fundamentals.
Via Chartmill · May 5, 2025
Here Are All the Dividend Kings Beating the S&P 500 in 2025 -- and the 2 That Are the Best Stocks to Buy Nowfool.com
Via The Motley Fool · May 5, 2025
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?fool.com
Via The Motley Fool · May 4, 2025
Johnson & Johnson - Elliott Wave Technical Analysistalkmarkets.com
We are tracking a potential major bottom forming in Primary wave 2. A clear five-wave move into wave {i} suggests the early stages of an upside trend resumption.
Via Talk Markets · May 2, 2025
40-Year-Old Making $4K a Month in Dividends Reveals His Top 8 Stocks — 'We Don't Wear Fancy Clothes or Spend Money on Impressing Others'benzinga.com
Via Benzinga · May 1, 2025
8 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · May 1, 2025
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?investors.com
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year?
Via Investor's Business Daily · May 1, 2025
Nvidia, Johnson & Johnson, Hyundai, Toyota, SoftBank CEOs To Join Trump At White House As He Touts Investment Surge In First 100 Days: Reportbenzinga.com
Trump to highlight investments from top companies, including Nvidia, J&J, and Toyota, in 'Investing in America' event to mark first 100 days in office.
Via Benzinga · April 29, 2025
Plaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medicationsbenzinga.com
A lawsuit claims Eli Lilly, Johnson & Johnson, and Kaiser Permanente failed to warn consumers about breast cancer risks linked to their antipsychotic drugs Risperdal and Zyprexa.
Via Benzinga · April 28, 2025
AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analystbenzinga.com
Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments.
Via Benzinga · April 28, 2025
3 Industry Behemoths Are Rewarding Investors With Dividend Bumps
See these three stocks that are among the most important in their industries, which have announced sizable increases in their dividends.
Via MarketBeat · April 28, 2025
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Druginvestors.com
The companies are working on treatments for a form of bladder cancer.
Via Investor's Business Daily · April 28, 2025
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.
Via MarketBeat · April 28, 2025
These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?fool.com
Via The Motley Fool · April 26, 2025
3 Dividend Kings That Have Raised Their Payouts in 2025fool.com
Via The Motley Fool · April 24, 2025